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Abstract
Background: Successful inhibition of alloimmune activation in organ transplantation remains one
of the key events in achieving a long-term graft survival. Since T lymphocytes are largely responsible
for alloimmune activation, targeted gene transfer of gene of cyclin kinase inhibitor p21 into T cells
might inhibit their aberrant proliferation. A number of strategies using either adenoviral or lentiviral
vectors linked to mono or bispecific antibodies directed against T cell surface markers/cytokines
did not yield the desired results. Therefore, this study was designed to test if a CD3promoter-p21
chimeric construct would in vitro and in vivo transfer p21 gene to T lymphocytes and result in
inhibition of proliferation. CD3 promoter-p21 chimeric constructs were prepared with p21 in the
sense and antisense orientation. For in vitro studies EL4-IL-2 thyoma cells were used and for in vivo
studies CD3p21 sense and antisense plasmid DNA was injected intramuscularly in mice.
Lymphocyte proliferation was quantified by 3H-thymidine uptake assay; IL-2 mRNA expression was
studied by RT-PCR and using Real Time PCR assay, we monitored the CD3, p21, TNF-α and IFN-
γ mRNA expression.
Results: Transfection of CD3p21 sense and antisense in mouse thyoma cell line (EL4-IL-2) resulted
in modulation of mitogen-induced proliferation. The intramuscular injection of CD3p21 sense and
antisense plasmid DNA into mice also modulated lymphocyte proliferation and mRNA expression
of pro-inflammatory cytokines.
Conclusion: These results demonstrate a novel strategy of in vitro and in vivo transfer of p21 gene
to T cells using CD3-promoter to achieve targeted inhibition of lymphocyte proliferation and
immune activation.
Background
Aberrant T lymphocyte proliferation is a key mediator of
alloimmune activation in organ transplantation. There-
fore, T cells are the key targets for direct transfer of genes
that could inhibit their proliferation and alloimmune
activation. A number of strategies using either adenoviral
or lentiviral vectors linked to mono or bispecific antibod-
ies directed against T cell surface markers/cytokines did
not yield the desired results [1-4]. The efficacy of a CD3
promoter-p21 chimeric construct to transfer p21 gene to T
lymphocytes was tested. Cyclin kinase inhibitor p21 is a
potent inhibitor of lymphocyte proliferation and inflam-
mation [5,6]. Inflammation is realized as one of the key
mediators of a number of diseases associated with aber-
rant cellular proliferation including alloimmune activa-
tion and organ transplant rejection. [7-12]. Transfer of
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genes into T cells remains a critical step to achieve success-
ful therapeutic strategies for such diseases. It is also clear
that resting T cells, which make up most of the circulating
T-cell pool in vivo, cannot be specifically and efficiently
transfected due to the presence of other immune cells in
the same milieu. The direct adenoviral and lentiviral vec-
tors mediated gene transfer to T cells was not successful
and the modification and coupling of these vectors with
antibodies to CD3 and other T cell surface receptors per-
mitted some limited success [1-4,13-16]. Interestingly,
expression of cyclins and cyclin-dependent kinases and
pro-inflammatory cytokines is increased during T lym-
phocyte proliferation [5]. Therefore, an effective control
of T cell proliferation by regulating the expression of cyc-
lins would potentially inhibit alloimmune activation and
inflammation. Cyclin kinase inhibitor p21 (here on after
only p21) is one of the most potent cyclin kinase inhibitor
and therefore has potential to control the expression of
cyclins and T cell activation. The inhibition of cyclin
dependent kinases and cyclins by p21 will prevent exces-
sive proliferation and prevent alloimmune activation by
the direct inhibition of T lymphocyte proliferation.
At the present time one of the most effective means to
inhibit T lymphocyte activation and alloimmune activa-
tion is with the immunosuppressive agents; cyclosporine
(CsA), tacrolimus (TAC) and sirolimus (SRL). However,
the long-term usage of these drugs leads to number of side
effects including nephrotoxicity, malignancy and viral
infections [17-19]. We have demonstrated that the T cell
inhibitory effects of CsA, TAC and SRL are in part medi-
ated by the induction of p21 [20-22]. Our studies have
also demonstrated in vitro and in vivo over-expression of
p21 in lymphocytes results in decreased response to
mitogenic stimuli and greater sensitive to the inhibitory
effects of CsA [23]. We have also shown that the over
expression of p21 in the recipients of rat heart transplant
recipients resulted in increased graft survival via the inhi-
bition of mRNA expression of pro-inflammatory
cytokines in allografts and lymphocytes [5]. Most signifi-
cantly, we recently demonstrated that the recombinant
p21 protein localizes into the nucleus, interacts with tran-
scription factors and inhibits lymphocyte proliferation
and markers of inflammation [24].
Therefore, the present study was designed to explore in
vitro and in vivo gene transfer of p21 targeted to T cells
using chimeric CD3 promoter-p21 constructs. For in vitro
studies, mouse thyoma cell line EL4, which constitutively
express T cell growth factor IL-2 were used. The in vivo
effects were evaluated by intramuscularly injecting CD3-
p21 sense and antisense plasmid DNA in mice. The results
demonstrate the feasibility p21 gene transfer targeted to T
cells with the CD3-p21 chimeric constructs with its bio-
logical consequences that is modulation of lymphocyte
proliferation and alloimmune activation.
Results
CD3Sensep21 and CD3AntiSensep21 constructs
A diagrammatic presentation of CD3p21 chimeric con-
struct with sequences of CD3 promoter, enhancer and
p21 genes in pSK plasmid is shown in Figure 1. Chimeric
constructs with p21 in the sense and anti-sense orienta-
tion are designated as CD3sense p21 and
CD3antisensep21, respectively.
Efficiency of Transfection
a) In vitro
Transfection efficiency was expressed as the percentage of
the total cells in the gated region that displayed green flu-
orescence, i.e. expressed in the pEGFP-p21 plasmid. A
mean of 76% ± 6 EL4-IL-2 cells were found to be positive
from three consecutive transfection experiments, com-
pared to completely negative for green fluorescence of
untransfected cells.
b) In vivo
Intramuscular injection of p21-EGFP plasmid DNA
resulted in increased expression of p21 and GFP mRNA in
splenocytes (only tissue studied). The expression of p21
mRNA was seen in 4/5 mice and GFP mRNA in 5/5 mice
(Figure 2B).
Targeted p21 overexpression inhibits IL-2 expression by 
EL4 thyoma cell lines
Transfection with CD3-p21 sense and antisense plasmid
DNA in EL4 thyoma cell lines resulted in modulation of
p21 gene expression. The results demonstrate that p21
mRNA expression was observed only in cells transfected
with, CD3-p21 sense plasmid DNA but not in cells trans-
fected with either empty vector (control) or CD3p21 anti-
sense plasmid DNA (lane 3, Figure 3A). Similar pattern
was observed with p21 protein expression (Figure 3B).
Efficacy of the transfection with CD3p21 sense and anti-
sense plasmid DNA was assessed by mRNA expression of
IL-2 in comparison with cells transfected with empty vec-
tor DNA. EL4-IL2, mouse T cells were transfected with
DNA from either sense or antisense CD3p21 constructs
using lipofectamine2000 (Gibco, Ling Island, USA). After
48 h, the cells were harvested, RNA was prepared and the
expression of IL-2 was studied by RT-PCR and compared
with untreated cells. The results in Figure 3C demonstrate
that in comparison with empty vector DNA transfected
cells (Control), the expression of IL-2 mRNA increased in
cells transfected with anti-sense (CD3ASp21) and
decreased in EL4-IL-2 cells treated with and sense plasmid
DNA (CD3Sp21). The expresion of the house keeping
gene β-actin in these cells was identical. Interestingly, theBMC Immunology 2006, 7:26 http://www.biomedcentral.com/1471-2172/7/26
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cells from CD3 Antisensep21 plasmid DNA transfected
proliferated more and CD3Sensep21 plasmid DNA trans-
fected proliferated less compared to untreated EL4-IL2
cells. These results demonstrate that it was feasible to
modulate p21 gene expression in T cell line using CD3p21
chimeric constructs. As a control, human adenocarcinoma
cells (A-549) and aortic smooth muscle cells were also
transfected with CD3p21 sense plasmid DNA and did not
result in increased p21 expression (data not shown).
Effect of Targeted p21 modulation on mitogen induced T 
cell proliferation and T cell growth factor (IL-2) mRNA 
expression
To study the effect of p21 modulation on mitogen
induced proliferation of T cells, EL4-IL-2 cells transfected
with CD3p21 sense and antisense plasmid DNA were acti-
vated with mitogen phytohemaglutinin (PHA). The pro-
liferation was quantified by 3H-thymidine uptake assay
and IL-2 expression was studied by RT-PCR after treat-
Construction of CD3-p21 chimeric plasmid conctruct Figure 1
Construction of CD3-p21 chimeric plasmid conctruct. A complete vector structure of pSK-CD3-p21 chimeric plasmid 
is shown. The restriction enzyme sites for CD3 promoter, enhancer and p21 gene are also shown. Plasmid TGE-CD3 contains 
the murine T cell-specific delta enhancer and promoter. CD3 promoter was cut with Pst I and blunted with T4 DNA polymer-
ase. HindIII linkers were ligated to the fragment and, following HindIII digestion, cloned into the HindIII site downstream of the 
enhancer region. The p21 gene was excised with restriction enzymes KpnI and XbaII, blunted with DNA polymerase I, large 
(Klenow) fragment, and cloned into the blunted Cla I site just downstream of the CD3 promoter in the enhancer/promoter SK 
construct.
BamH I
CD3 Enhancer
BamH I
Hind III
CD3 Promoter
Hind III
Cla I blunt
p21 (1.7 Kb) Cla I blunt
pSK-CD3p21~6392 bp
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ment of these cells with PHA for 4 hours. The results
shown in Figure 4A demonstrate the inability of EL4-IL2
cells transfected with CD3Sensep21 plasmid DNA to pro-
liferate in response to mitogenic stimulus with PHA. Inter-
estingly, EL4IL-2 cells transfected with CD3Antisensep21
plasmid DNA proliferated significantly (p < 0.02) more
compared to the empty vector transfected cells. These
results indicate the ability of CD3p21 chimeric constructs
to alter proliferation of mouse T cells, by altering p21
expression.
EL4IL-2 cells transfected with either CD3Sensep21 or
CD3Antisensep21 constructs were treated with PHA (1
μg/ml) for 4 hours, RNA was isolated and expression of
IL-2 mRNA was studied by RT-PCR. The results shown in
the Figure 4B demonstrate the increase in IL-2 expression
only in EL4IL2 cells transfected with CD3Antisensep21
plasmid DNA. The increased IL-2 expression correlated
with the proliferation of these cells in response to PHA.
In vivo efficacy of CD3p21 sense and antisense plasmid 
DNA in mice
12 mice (C57/BL-6) were divided into three groups (n = 8
in each group). Mice were intramuscularly injected with
either empty vector plasmid DNA, or CD3p21 sense or
antisense plasmid DNA (100 μg). Mice were sacrificed
after day 7 and splenocytes were prepared and activated
with antiCD3 monoclonal antibody. First, we confirmed
the presence of CD3 and p21 mRNA in lymphocytes from
mice injected with CD3p21 sense or antisense plasmid
DNA. The results (Figure 5A) demonstrate the presence of
both CD3 and p21 mRNA in mice injected with
CD3Sensep21 compared to only CD3 mRNA in mice
injected with CD3Antisensep21 plasmid DNA. The results
(Figure 5B) also indicate that splenocytes from mice trans-
fected with CD3p21 mice proliferated significantly (p <
0.01) less than controls (Mean ± SEM 47264 ± 5805 vs
69729 ± 3333) and than mice transfected with CD3Asp21
plasmid DNA (104163 ± 2381, p < 0.001). The real time
PCR analysis of these anti-CD3 activated lymphocytes
demonstrated a TNF-α (35 fold) and IFN-γ (27 fold)
increased mRNA expression in lymphocytes from CD3
antisensep21 plasmid DNA compared to CD3Sensep21
plasmid injected mice (Figure 5C).
Discussion
The principal aim for this chimeric plasmid was to test the
T cell targeted overexpression of p21 in T lymphocytes,
since CD3 is surface marker for only T lymphocytes. We
have earlier described the efficacy of p21 sense and anti-
sense plasmid DNA to either overexpress or delete p21
gene in lymphoid and non-lymphoid cell lines [23].
Alloimmune activation remains a critical step in allograft
rejection and survival. Therefore, a strategy, which could
specifically target T lymphocytes, will provide an effective
inhibition of alloimmune activation permitting pro-
longed graft survival. Our studies [5,23,24] have demon-
strated that p21 is such an agent since it is a potent
inhibitor of lymphocyte proliferation. Our studies have
shown that its over expression not only renders lym-
phocytes less responsive to mitogenic and allogenic stim-
uli but also makes them more responsive to other anti-
inflammatory agents such as CsA [23]. Our in vitro studies
with another T cell line (Jurkat T cells) have also demon-
strated that the overexpression of p21 resulted in their
unresponsiveness to mitogenic stimuli [5,23]. These
results demonstrate that p21 can be utilized as an effective
agent to specifically target T lymphocytes to limit inflam-
mation. Interestingly, mCD3delta promoter has been
shown contributes largely to a T cell-specific expression
pattern both in vitro and in transgenic mouse studies [1],
supporting our studies with CD3promoter-p21 chimeric
gene construct. Studies have also demonstrated that aden-
oviral vectors coupled to bispecific antibodies (bsAbs)
with one of the antibodies to CD3 could target T cells that
were normally resistant to adenoviral vectors. Similarly,
surface-engineered lentiviral vectors significantly
improved transduction of primary lymphocytes by acti-
vating the target cells [2]. But the results from these exper-
iments explain the ability of a nonviral vector to directly
Construction and efficacy of p21-EGFP construct Figure 2
Construction and efficacy of p21-EGFP construct. 
p21-EGFP constructs were prepared by ligating p21 gene 
construct in Multiple Cloning Site of EGFP vector. Colonies 
were picked and amplified for p21 and GFP gene expression. 
A. The results of PCR amplification of two representative 
colonies are shown. DNA from colony #2 (lanes 2 and 4) 
exhibits stronger gene expression for both p21 and GFP 
compared to colony #1 (lanes 1 and 3). More DNA was 
prepared from colony #2 and used to assess in vivo efficiency 
of transfection using intramuscular injection. B: Efficacy of 
intramuscular injection of p21-GFP plasmid DNA is shown as 
p21 and GFP mRNA expression in splenocytes individually 
from 5 mice.
p21
EGFP
1     2     3     4     5
100 bp 1    2         3    4
p21 EGFP
Number of Mice
A
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transfer genes to T cell s with CD3 promoter gene con-
struct.
A number of studies [1-4] have explored the efficacy of
adenoviral or lentiviral vectors with different combina-
tions of antibodies to MHC-1, T cell receptor (TCR)-CD3+
cytokine +chemokine to provide gene therapeutic
approach for cancer treatment to bypass tumor immune
mechanisms. However, in this study, the efficacy of a non-
viral CD3p21 chimeric plasmid construct to effectively in
vivo modulate p21 expression is provided. Previous stud-
ies have demonstrated that the overexpression of p21
induced by intramuscular injection of p21 sense plasmid
DNA resulted in an increased graft survival in a rat heart
transplant model [5]. The method of using plasmid DNA
to obtain in vitro and in vivo transfection of p21 is based
on the data supporting the efficacy of intra-muscular
injection of plasmid DNA for a number of genes [25-27].
Efficacy of CD3-p21 chimeric plasmid DNA Figure 3
Efficacy of CD3-p21 chimeric plasmid DNA. The efficacy of CD3-p21 plasmid DNA in mouse Thyoma cells. T cells were 
transfected as described in Material and Methods section, and studied for presence of p21 mRNA and protein expression. A: 
p21 mRNA expression: The expression of p21 mRNA is seen only in cells transfected with CD3Sp21 sense plasmid DNA 
(lane 1) compared to cells transfected with either CD3ASp21 plasmid DNA (lane 2) or the empty vector DNA (lane 3). An 
equal expression of β-actin, a house-keeping gene for these three representative cell lines is also shown. B: p21 protein 
expression: Comparisom of expression of p21 protein in the control DNA (lane 1), CD3Sp21 (lane 2) and CD3ASp21 
(lane 3) transfected cells, is shown in Western blot analysis of p21 protein. C: IL-2 mRNA expression: The expression of 
Il-2 mRNA in cells transfected with CD3Sp21 DNA is almost inhibited (lane 3) compared to cells transfected with the empty 
vector DNA (Lane 1), where as IL-2 mRNA is increased in CD3Asp21 DNA transfected cells (Lane 2). An equal expression 
of β-actin, a house-keeping gene for these three representative cell lines is also shown for each transfection. CD3Sp21 = 
CD3sensep21 and CD3ASp21 = CD3Antisensep21 plasmid DNA
A
B
Control CD3Sp21          CD3ASp21 Control CD3Sp21          CD3ASp21 Control CD3Sp21          CD3ASp21
Control   CD3ASp21   CD3Sp21
β-actin
IL-2
Control   CD3ASp21   CD3Sp21
β-actin
IL-2
p21
β-actin
CD3S21    CD3ASp21   Control
p21
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CD3S21    CD3ASp21   Control
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Intramuscular injection of naked plasmid DNA expres-
sion vectors encoding either TGF-beta1 (pVR-TGF-beta1)
or an IL-4-IgG1 chimeric protein (pVR-IL-4-IgG1) resulted
in production of TGF-beta1 or IL-4-IgG1, respectively, and
protection from myelin basic protein (MBP)-induced
experimental allergic encephalomyelitis (EAE) [28]. The
in vivo specificity and efficiency of nonviral vectors has
been demonstrated for IL-10 was found to be far more
persistent than those achieved by viral vectors [29]. Simi-
lar results have been reported for a number of genes with
a single intramuscular injection suggesting that the mus-
cle tissue is accessible and expression is usually more per-
sistent than elsewhere, vector administration is simple
and the method is inexpensive. More significantly, plas-
mids do not induce neutralizing immunity, which per-
mits repeated administration. One of the earlier criticisms
of this methodology was that effect of gene modulation in
immune cells might not be achieved but this and other
studies [25-27] more significantly in human [30] demon-
strates the feasibility of the gene transfer using plasmid
DNA. Our method of in vitro and in vivo modulation of
gene expression was very efficient.
Therefore, based on our published studies [5,20] and the
results from this study, we demonstrate that the p21 over-
expression obtained through direct gene transfer to T cells
via intramuscular injections of CD3-p21 plasmid DNA
results in the decreased responsiveness of T lymphocytes
to mitogenic stimuli. Linearized DNA containing the
CD3-p21 construct was used to overexpress p21 both in
vitro (EL4-IL-2 cell line) and in vivo in mice (C57BL/6).
These results uniquely describe the construction of a chi-
meric plasmid construct constituted of CD3 promoter and
cyclin kinase inhibitor p21. The results demonstrate the
feasibility of direct gene transfer to T cells with a
CD3promoter-p21 chimeric construct.
Conclusion
In summary, the results from this study uniquely
describes the feasibilty of direct gene transfer into T cells
with a chimeric CD3-p21 plasmid construct. The transfec-
tion of EL4 thymoma cells, which constitutively express
IL-2 mRNA, using DNA with p21 in the sense and anti-
sense direction resulted in modulation of T cell prolifera-
tion. The extent of cellular proloferation correlated with
IL-2 mRNA expression. Most significantly, intramuscular
injection of the CD3p21 sense and antisense plasmid
DNA resulted in increased p21 expresion in T cells con-
firmed by the expression of CD3 and p21 mRNA expres-
sion. This overexpression resulted in unresponisveness of
splenocytes from these mice to mitigen-induced prolofer-
ation. However, we did not explore the effect of p21 over-
expression in subsets of T lymphocytes such as CD4 and
CD8 cells, which may have different response. Further-
more, based on its effect on immunomodulation, it is
likely that p21 plays an important role in genertaion and
maintrenance of CD4+CD25+ T regulatoruy cells, which
need to be explored. The ultimate goal of such a study is
to utilize this methodology to target T cells to modulate
gene expression in T cells responsible for site specific
inflammation and alloimmune activation. The targeted
Effect of direct p21 gene transfer in T cells on mitogen  induced proliferation Figure 4
Effect of direct p21 gene transfer in T cells on 
mitogen induced proliferation. Three cell lines each 
from cells transfected with CD3p21 sense and CD3p21 anti-
sense plasmid DNA were cultured with and without PHA for 
4 h for IL-2 mRNA expression and 72 h (last 16 h with 3H-
thymidine) for the proliferation assay. The results (A) dem-
onstrate that p21 overexpressing EL4 T cells (CD3Sp21) did 
not respond to the mitogenic stimulus, whereas cells trans-
fected with antisense plasmid DNA (CD3ASp21) proliferated 
significantly higher compared to untreated cells. *** = p < 
0.02 (EL4 CD3ASp21 cells control vs PHA), ** = p < 0.03 
EL4CD3Sp21 PHA vs CD3Asp21 PHA) and * = p < 0.05 con-
trol EL4 cells vs PHA. The mitogenic response was reflected 
in IL-2 mRNA expression by these cells. There was no differ-
ence in IL-2 mRNA expression between untreated and cells 
cultured with PHA for CD3Sensep21 plasmid DNA trans-
fected cells (B, lanes 1 with a and without PHA). In sharp 
contrast, in cells transfected with CD3Antisensep21 plasmid 
DNA, PHA treatment resulted in a significant increase in IL-2 
mRNA expression compared to the untreated cells.
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In vivo effects of direct transfer of p21 gene in mice Figure 5
In vivo effects of direct transfer of p21 gene in mice. A: modulation of p21 gene expression: Group of mice (n = 
24) were injected intramuscularly with either empty vector, CD3p21 sense, CD3p21 Antisense plasmid DNA (n = 8 each). 
Modulation of p21 was monitored by p21 mRNA expression using Real Time PCR analysis of lymphocytes. Results from repre-
sentative 2 animals from each group are shown. The mRNA expresion of both p21 and CD3 is seen only in mice injected with 
CD3p21 sense plasmid DNA, whereas as expected only CD3 mRNA expression is detectable in mice injected with empty vec-
tor plasmid DNA. These results demonstrate the ability of CD3p21 sense plasmid DNA to modulate p21 gene in T lym-
phocytes. B: In vivo effect of p21 overexpression on lymphocyte proliferation. Lymphocytes from mice injected with 
empty vector plasmid DNA (control mice n = 7), CD3p21 sense and antisense plasmid DNA (n = 7) were isolated and the pro-
liferation in response to murine anti-CD3 monoclonal antibody was quantified using 3H-thymidine uptake assay. The lym-
phocytes from mice injected with CD3p21 sense plasmid DNA proliferated significantly (p < 0.01) less and with CD3p21 
antisense plasmid DNA proliferated significantly (p < 0.001) more compared to the control mice. These results demonstrate 
that the direct gene modulation in T cells can influence their proliferation and inflammation. C: In vivo effect of p21 modu-
lation on TNF-α and IFN-γ mRNA expression: RNA from lymphocytes obtained from mice injected with CD3Sp21 and 
CD3ASp21 plasmid DNA were isolated, reverse transcribed and analyzed for TNF-α and IFN-γ mRNA expression using Real 
Time PCR assay. Fold increase of mRNA expression in lymphocytes from CD3Antisensep21 injected mice was calculated with 
respect to the CD3Sensep21 DNA injected mice.
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overexpression of p21 in T lymphocytes to inhibit their
proliferation and subsequently inflammation will provide
the most suitable therapeutic strategy to inhibit alloim-
mune activstion in organ transplantation. This can only
be accompalished using a gene therapeutic technique.
Using various gene transfer technologies, the ability to
transfer genes to the various cell types within whole ani-
mals has been describing allowing a wishful thinking to
prevent and treat many diseases. It is therefore conceived
that that the studies like this would pave the way to the
development of such tools not just to treat disease but
also to study the physiology of the healthy body. The abil-
ity to target tissue specific gene to alter the products (genes
and proteins) responsible for a specific signaling or bio-
synthetic pathway, will be extremely beneficial. Thouogh
these strategies seem possible however many hurdles and
challenges that include efficient in vitro and in vivo trans-
fection need to be overcome. But the studies like this if
confirmed in a number of other models will provide an
unique direction in the development of targeted gene
therapeutic approaches to prevent not only only alloim-
mune activation in organ transplantation but also inflam-
mtion in patients with cancer, arthritis, inflammatory
bowel disease and others diseases associated with aber-
rant cellular proliferation like atherosclerosis.
Methods
Construction of CD3p21 chimeric constructs
Plasmid TGE-CD3 containing the murine T cell-specific
delta enhancer and promoter was originally obtained
from Dr Ronald Evans (Salk Institute, San Diego, CA).
This CD3 promoter containing plasmid has successfully
been shown to target genes specifically to T cells [31]. The
enhancer region was isolated from the plasmid following
restriction digestion with BamHI and cloned into the
BamHI site of the pBluescript SK vector (Stratagene, La
Jolla, CA). The murine CD3 promoter was cut with Pst I
and blunted with T4 DNA polymerase. HindIII linkers
were ligated to the fragment and, following HindIII diges-
tion, cloned into the HindIII site downstream of the
enhancer region. The p21 gene was excised from the zeo+-
p21 plasmid construct [23] with restriction enzymes KpnI
and XbaII, blunted with DNA polymerase I, large (Kle-
now) fragment, and cloned into the blunted Cla I site just
downstream of the CD3 promoter in the enhancer/pro-
moter SK construct. Proper orientation of all components
was confirmed by sequence analysis. The transgene was
then separated from plasmid sequences following restric-
tion enzyme digestion, agarose gel electrophoresis, and
electro elution. The presence of p21 gene and its orienta-
tion (sense and antisense) was confirmed by DNA
sequencing. A number of clones expressing p21 gene in
the sense or anti-sense orientation were obtained and
termed as CD3 Antisensep21 and CD3Sensep21 con-
structs. Plasmid DNA from these clones was prepared and
the presence of p21 gene was ascertained by separating
restriction enzyme digested DNA on agarose gels.
EL4-Thymoma cells Proliferation Assay
Cell proliferation was determined using 3H-thymidine
incorporation assay as previously described [5]. All assays
were performed in triplicate. A total of 3 individual exper-
iments investigating the proliferation of unaltered and
p21 EL4-Thyoma cells were performed in un-stimulated
and activated with PHA. Briefly, 200,000 cells were added
to each well of a round bottom 96-well plate. PHA (2 μg/
ml) was added to the wells, controls were without PHA.
The cells were cultured for 64 h at 37°C in 95% air and
5% CO2 enriched environment. The cultures were pulsed
with 3H Thymidine (1 μCi/well) for the last 16 h of incu-
bation, cells were harvested and radioactivity counted
using a scintillation counter. 3H-Thymidine uptake was
expressed as the mean counts per minute of triplicate sam-
ples. The magnitude of EL4-Thyoma T cells proliferation
from unaltered and p21-augmented cells was investigated
at rest and following mitogen stimulation.
In vitro transfection of p21WAF1/CIP1
EL4 cells were transfected with CD3Sensep21,
CD3Antisensep21 DNA as described earlier [23]. The
increased or decreased level of p21 mRNA and protein
expression was determined by RT-PCR and Western blot,
respectively [20,21]. Cells transfected with empty vector
plasmid DNA were used as controls.
In vivo transfection of p21WAF1/CIP1
Mice (C57BL/6) were obtained from Jackson Labs. 8–12
week old mice of either sex, mice (n = 24) were non-
injected (n = 8), injected with empty (n = 8), vector or
injected with p21 100 μg of sense plasmid DNA (n = 8)
and p21 100 μg of antisense plasmid DNA (n = 8) com-
plexed with lipofectamine. Mice were sacrificed 7 days
after the last DNA injection. Lymphocytes were isolated
and the spontaneous and anti-CD3 induced ex vivo prolif-
eration was studied. The efficacy of gene transfer was
monitored by real time PCR analysis of p21 and CD3
mRNA in splenocytes.
In vitro and in vivo efficiency of Transfection
In vitro and in vivo efficiency of our method of transfection
was assessed by transfection of EL4-IL-2 thyoma cells and
mice with p21-GFP construct, respectively. The authentic-
ity of p21-GFP construct is shown in Figure 2A. For in vitro
assay, cells were transfected with p21-GFP construct and
cells were washed and the percent of cells positive for
green fluorescence were counted using Fluorescence Acti-
vated Cell Sorter. Untransfected and cells transfected with
empty plasmid DNA were used as controls. For in vivo effi-
ciency of our method, 5 mice were injected (intramuscu-
lar) with 100 μg of p21-GFP DNA or empty vectorBMC Immunology 2006, 7:26 http://www.biomedcentral.com/1471-2172/7/26
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plasmid DNA. After 7 days, mice were sacrificed and RNA
was isolated from spleens, reverse transcribed to cDNA
and amplified for p21 and GFP mRNA.
Detection of mRNA by reverse transcription and 
polymerase chain reaction (PCR) in lymphocytes
Total RNA was isolated from lymphocytes with Trizol
(Invitrogen, Carlsbad, CA) and tissues with SV RNA isola-
tion kit (Promega, Madison, WI). Purity of RNA was con-
firmed by a ratio of 260/280 nm. 1 μg of RNA was reverse
transcribed into cDNA using a superscript reverse tran-
scription kit from Invitrogen (Carlsbad CA). The amplifi-
cation of specific mRNA expression was achieved by
polymerase chain reaction (PCR) using specific primer
sequences for p21, β-actin, IL-2 are described by us [5].
The PCR products were resolved in 1% agarose gel electro-
phoresis, ethidium bromide stained specific bands were
visualized under UV light and photographed. A cycle anal-
ysis was performed for each primer pair to select a cycle
number for amplification for each gene studied.
Detection of mRNA by Real Time PCR
We performed real-time quantitative RT-PCR for CD3,
p21, TNF-α and IFN-γ mRNA using a Bio-Rad iCycler sys-
tem (Bio-Rad, Hercules, CA). RNAs were isolated from
renal tissues using a kit from Promega (Madison, USA)
and reverse-transcribed into cDNAs by using a cDNA syn-
thesis kit from invitrogen (Carlsbad CA). The specificity of
primers (CD3  Sense 5'-TGCTCTTGGTGTATATCT-
CATTGC-3', antisense 5'-CAGA GTCTGCTTGTCT-
GAAGCTC-3';  p21  Sense 5'-TCACTGTCTTGTACCCTT
GTGC-3', antisense 5'-GGCGTTTGGAGTGGTAGAAA-3';
IFN-γ  Sense 5'-TCTGGAGGA ACTGGCAAAAG-3', anti-
sense 5'-TTCAAGACTTCAAAGAGTC TGAGG-3'; TNF-α
Sense 5'-GACAAGCCTGTAGC CCATGT-3', antisense 5'-
TCTCAGCTCC ACGCCATT-3' and β-actin  sense: 5'-
CCCAGCAC AAT GA AGATCAA-3' and antisense 5'-CGAT
CCACACGG AGTACTTG-3) was tested by running a regu-
lar PCR for 40 cycles at 95°C for 20 s and 60°C for 1
minute, and followed separating in ethidium bromide
containing agarose gels. The real-time PCR was performed
using a SYBR supermix kit (Bio-RAD), and running for 40
cycles at 95°C for 20 s and 60°C for 1 minute. The PCR
efficiency was also examined by serially diluting the tem-
plate cDNA and the melting curve data was collected to
check the PCR specificity and proper negative controls
were included in each assay. The mRNA level for each
gene for each sample was normalized to β-actin mRNA
and was presented as 2 [(Ct/β-actin – Ct/gene of interest)]
as described [32].
Data analysis
Differences between groups were determined using two-
tailed unpaired T test with significance considered present
at a p value of less than 0.05. Statistical analysis was per-
formed using a software program from GraphPad Soft-
ware, Inc., San Diego, CA 92121 USA. The results are
expressed as M ± SEM.
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